Imprimis Pharmaceuticals, Inc. (IMMY) Issues Quarterly Earnings Results, Beats Estimates By $0.29 EPS

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) released its quarterly earnings results on Thursday. The specialty pharmaceutical company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.29, Morningstar.com reports. The business had revenue of $6.86 million for the quarter. Imprimis Pharmaceuticals had a negative net margin of 90.48% and a negative return on equity of 388.64%.

Imprimis Pharmaceuticals (NASDAQ IMMY) traded down 0.95% during midday trading on Friday, reaching $2.09. 339,701 shares of the company were exchanged. The firm’s market capitalization is $41.94 million. Imprimis Pharmaceuticals has a 52 week low of $1.65 and a 52 week high of $4.69. The company has a 50-day moving average of $2.87 and a 200 day moving average of $3.12.

Several research firms have recently issued reports on IMMY. ValuEngine lowered shares of Imprimis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 16th. Zacks Investment Research cut shares of Imprimis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 16th.

In other Imprimis Pharmaceuticals news, Director Robert J. Kammer sold 10,000 shares of the business’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $3.05, for a total value of $30,500.00. Following the completion of the transaction, the director now directly owns 1,059,827 shares in the company, valued at $3,232,472.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 12.55% of the company’s stock.

Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its stake in shares of Imprimis Pharmaceuticals by 60.7% in the second quarter. Bank of New York Mellon Corp now owns 35,606 shares of the specialty pharmaceutical company’s stock worth $114,000 after buying an additional 13,455 shares in the last quarter. Wealthsource Partners LLC bought a new stake in Imprimis Pharmaceuticals during the first quarter valued at approximately $125,000. KCG Holdings Inc. bought a new stake in Imprimis Pharmaceuticals during the first quarter valued at approximately $130,000. Apollo Management Holdings L.P. bought a new stake in Imprimis Pharmaceuticals during the first quarter valued at approximately $417,000. Finally, Granite Investment Partners LLC raised its stake in Imprimis Pharmaceuticals by 109.0% in the first quarter. Granite Investment Partners LLC now owns 297,297 shares of the specialty pharmaceutical company’s stock valued at $1,239,000 after buying an additional 155,071 shares in the last quarter. Hedge funds and other institutional investors own 17.12% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://sportsperspectives.com/2017/08/11/imprimis-pharmaceuticals-inc-immy-issues-quarterly-earnings-results-beats-estimates-by-0-29-eps.html.

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.

Earnings History for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Receive News & Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply